Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Arthritis Research & Therapy
Erschienen in: Arthritis Research & Therapy 1/2003

01.02.2003 | Review

Natural killer cells and autoimmunity

verfasst von: Anthony R French, Wayne M Yokoyama

Erschienen in: Arthritis Research & Therapy | Ausgabe 1/2003

Einloggen, um Zugang zu erhalten

Abstract

Autoimmune diseases are often characterized as clinical syndromes caused by the inappropriate activation of T or B cells resulting in systemic or organ-specific damage. However, studies support a role for the innate immune system, and in particular natural killer (NK) cells, in stimulating or suppressing autoimmunity. This review focuses on recent research elucidating a potential immunoregulatory role for NK cells in modulating T and B cell-mediated autoimmunity.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Yokoyama WM: Natural killer cell receptors. Curr Opin Immunol. 1998, 10: 298-305. 10.1016/S0952-7915(98)80168-4.CrossRefPubMed
2.
Seaman WE: Natural killer cells and natural killer T cells. Arthritis Rheum. 2000, 43: 1204-1217. 10.1002/1529-0131(200006)43:6<1204::AID-ANR3>3.0.CO;2-I.CrossRefPubMed
3.
Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP: Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999, 17: 189-220. 10.1146/annurev.immunol.17.1.189.CrossRefPubMed
4.
French AR, Yokoyama WM: Natural killer cells and viral infections. Curr Opin Immunol. 2003, 15: 45-51. 10.1016/S095279150200002X.CrossRefPubMed
5.
Horwitz DA, Gray JD, Ohtsuka K, Hirokawa M, Takahashi T: The immunoregulatory effects of NK cells – the role of TGF-β and implications for autoimmunity. Immunol Today. 1997, 18: 538-542. 10.1016/S0167-5699(97)01149-3.CrossRefPubMed
6.
Fearon DT, Locksley RM: The instructive role of innate immunity in the acquired immune response. Science. 1996, 272: 50-53.CrossRefPubMed
7.
Kos FJ: Regulation of adaptive immunity by natural killer cells. Immunol Res. 1998, 17: 303-312.CrossRefPubMed
8.
Su HC, Nguyen KB, Salazar-Mather TP, Ruzek MC, Dalod MY, Biron CA: NK cell functions restrain T cell responses during viral infections. Eur J Immunol. 2001, 31: 3048-3055. 10.1002/1521-4141(2001010)31:10<3048::AID-IMMU3048>3.0.CO;2-1.CrossRefPubMed
9.
Zitvogel L: Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med. 2002, 195: F9-F14. 10.1084/jem.20012040.PubMedCentralCrossRefPubMed
10.
Lanier LL: NK cell receptors. Annu Rev Immunol. 1998, 16: 359-393. 10.1146/annurev.immunol.16.1.359.CrossRefPubMed
11.
Campbell KS, Colonna M: Human natural killer cell receptors and signal transduction. Int Rev Immunol. 2001, 20: 333-370.CrossRefPubMed
12.
Moretta L, Biassoni R, Bottino C, Cantoni C, Pende D, Mingari MC, Moretta A: Human NK cells and their receptors. Microbes Infect. 2002, 4: 1539-1544. 10.1016/S1286-4579(02)00037-0.CrossRefPubMed
13.
Yokoyama WM, Plougastel BF: Immune functions encoded by the natural killer gene complex. Nat Rev Immunol. 2003, 3: 304-316. 10.1038/nri1055.CrossRefPubMed
14.
Ljunggren HG, Karre K: In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990, 11: 237-244. 10.1016/0167-5699(90)90097-S.CrossRefPubMed
15.
Raulet DH: Development and tolerance of natural killer cells. Curr Opin Immunol. 1999, 11: 129-134. 10.1016/S0952-7915(99)80023-5.CrossRefPubMed
16.
Raulet DH, Vance RE, McMahon CW: Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol. 2001, 19: 291-330. 10.1146/annurev.immunol.19.1.291.CrossRefPubMed
17.
Lanier LL: On guard – activating NK cell receptors. Nat Immunol. 2001, 2: 23-27. 10.1038/83130.CrossRefPubMed
18.
Diefenbach A, Raulet DH: Strategies for target cell recognition by natural killer cells. Immunol Rev. 2001, 181: 170-184. 10.1034/j.1600-065X.2001.1810114.x.CrossRefPubMed
19.
Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L: Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001, 19: 197-223. 10.1146/annurev.immunol.19.1.197.CrossRefPubMed
20.
Smith HR, Idris AH, Yokoyama WM: Murine natural killer cell activation receptors. Immunol Rev. 2001, 181: 115-125. 10.1034/j.1600-065X.2001.1810109.x.CrossRefPubMed
21.
Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T: Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol. 2001, 2: 255-260. 10.1038/85321.CrossRefPubMed
22.
Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T, Bukowski JF: MICA engagement by human Vγ2Vδ2 T cells enhances their antigen-dependent effector function. Immunity. 2001, 15: 83-93. 10.1016/S1074-7613(01)00168-6.CrossRefPubMed
23.
Tieng V, Le Bouguenec C, du Merle L, Bertheau P, Desreumaux P, Janin A, Charron D, Toubert A: Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc Natl Acad Sci USA. 2002, 99: 2977-2982. 10.1073/pnas.032668099.PubMedCentralCrossRefPubMed
24.
Grunebaum E, Malatzky-Goshen E, Shoenfeld Y: Natural killer cells and autoimmunity. Immunol Res. 1989, 8: 292-304.CrossRefPubMed
25.
Flodstrom M, Shi FD, Sarvetnick N, Ljunggren HG: The natural killer cell – friend or foe in autoimmune disease?. Scand J Immunol. 2002, 55: 432-441. 10.1046/j.1365-3083.2002.01084.x.CrossRefPubMed
26.
Baxter AG, Smyth MJ: The role of NK cells in autoimmune disease. Autoimmunity. 2002, 35: 1-14. 10.1080/08916930290005864.CrossRefPubMed
27.
Yanagihara Y, Shiozawa K, Takai M, Kyogoku M, Shiozawa S: Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA). Clin Exp Immunol. 1999, 118: 131-136. 10.1046/j.1365-2249.1999.01018.x.PubMedCentralCrossRefPubMed
28.
Koreck A, Suranyi A, Szony BJ, Farkas A, Bata-Csorgo Z, Kemeny L, Dobozy A: CD3+CD56+ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis. Clin Exp Immunol. 2002, 127: 176-182. 10.1046/j.1365-2249.2002.01721.x.PubMedCentralCrossRefPubMed
29.
Bossowski A, Urban M, Stasiak-Barmuta A: Analysis of circulating T gamma/delta lymphocytes and CD16/56 cell populations in children and adolescents with Graves' disease. Pediatr Res. 2003, 54: 425-429. 10.1203/01.PDR.0000076663.94850.44.CrossRefPubMed
30.
Ciampolillo A, Guastamacchia E, Amati L, Magrone T, Munno I, Jirillo E, Triggiani V, Fallacara R, Tafaro E: Modifications of the immune responsiveness in patients with autoimmune thyroiditis: evidence for a systemic immune alteration. Curr Pharm Des. 2003, 9: 1946-1950. 10.2174/1381612033454270.CrossRefPubMed
31.
Cameron AL, Kirby B, Griffiths CE: Circulating natural killer cells in psoriasis. Br J Dermatol. 2003, 149: 160-164. 10.1046/j.1365-2133.2003.05319.x.CrossRefPubMed
32.
O'Gorman M, Smith R, Garrison A, Shamiyeh E, Pachman L: Lymphocyte subsets in peripheral blood from newly diagnosed, untreated patients with juvenile dermatomyositis (JDM) are associated with disease activity scores (DAS). Arthritis Rheum. 2002, 46 (suppl 9): S490-
33.
Yabuhara A, Yang FC, Nakazawa T, Iwasaki Y, Mori T, Koike K, Kawai H, Komiyama A: A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol. 1996, 23: 171-177.PubMed
34.
Wouters CH, Ceuppens JL, Stevens EA: Different circulating lymphocyte profiles in patients with different subtypes of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002, 20: 239-248.PubMed
35.
Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W: Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford). 2003, 42: 375-379. 10.1093/rheumatology/keg074.CrossRef
36.
Imashuku S, Hyakuna N, Funabiki T, Ikuta K, Sako M, Iwai A, Fukushima T, Kataoka S, Yabe M, Muramatsu K, Kohdera U, Nakadate H, Kitazawa K, Toyoda Y, Ishii E: Low natural killer activity and central nervous system disease as a high-risk prognostic indicator in young patients with hemophagocytic lymphohistiocytosis. Cancer. 2002, 94: 3023-3031. 10.1002/cncr.10515.CrossRefPubMed
37.
Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A: Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003, 142: 292-296. 10.1067/mpd.2003.110.CrossRefPubMed
38.
Erkeller-Yusel F, Hulstaart F, Hannet I, Isenberg D, Lydyard P: Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus. Lupus. 1993, 2: 227-231.CrossRefPubMed
39.
Erkeller-Yuksel FM, Lydyard PM, Isenberg DA: Lack of NK cells in lupus patients with renal involvement. Lupus. 1997, 6: 708-712.CrossRefPubMed
40.
Munschauer FE, Hartrich LA, Stewart CC, Jacobs L: Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J Neuroimmunol. 1995, 62: 177-181. 10.1016/0165-5728(95)00115-9.CrossRefPubMed
41.
Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW: A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J Neuroimmunol. 1998, 86: 123-133. 10.1016/S0165-5728(98)00014-9.CrossRefPubMed
42.
Riccieri V, Spadaro A, Parisi G, Taccari E, Moretti T, Bernardini G, Favaroni M, Strom R: Down-regulation of natural killer cells and of gamma/delta T cells in systemic lupus erythematosus. Does it correlate to autoimmunity and to laboratory indices of disease activity?. Lupus. 2000, 9: 333-337. 10.1191/096120300678828460.CrossRefPubMed
43.
Takahashi K, Miyake S, Kondo T, Terao K, Hatakenaka M, Hashimoto S, Yamamura T: Natural killer type 2 bias in remission of multiple sclerosis. J Clin Invest. 2001, 107: R23-R29.PubMedCentralCrossRefPubMed
44.
Biron CA, Byron KS, Sullivan JL: Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med. 1989, 320: 1731-1735.CrossRefPubMed
45.
Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T: Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol. 1996, 103: 408-413.PubMedCentralCrossRefPubMed
46.
Orange JS: Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect. 2002, 4: 1545-1558. 10.1016/S1286-4579(02)00038-2.CrossRefPubMed
47.
Lamy T, Loughran TP: Clinical features of large granular lymphocyte leukemia. Semin Hematol. 2003, 40: 185-195. 10.1016/S0037-1963(03)00133-1.CrossRefPubMed
48.
Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL: Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood. 1994, 84: 2721-2725.PubMed
49.
Rabbani GR, Phyliky RL, Tefferi A: A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol. 1999, 106: 960-966. 10.1046/j.1365-2141.1999.01624.x.CrossRefPubMed
50.
Martin MP, Nelson G, Lee JH, Pellett F, Gao X, Wade J, Wilson MJ, Trowsdale J, Gladman D, Carrington M: Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol. 2002, 169: 2818-2822.CrossRefPubMed
51.
van der Slik AR, Koeleman BP, Verduijn W, Bruining GJ, Roep BO, Giphart MJ: KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes. 2003, 52: 2639-2642.CrossRefPubMed
52.
Takeno M, Shimoyama Y, Kashiwakura JI, Nagafuchi H, Sakane T, Suzuki N: Abnormal killer inhibitory receptor expression on natural killer cells in patients with Behcet's disease. Rheumatol Int. 2003, [epub ahead of print]
53.
Namekawa T, Snyder MR, Yen JH, Goehring BE, Leibson PJ, Weyand CM, Goronzy JJ: Killer cell activating receptors function as costimulatory molecules on CD4+CD28null T cells clonally expanded in rheumatoid arthritis. J Immunol. 2000, 165: 1138-1145.CrossRefPubMed
54.
Warrington KJ, Takemura S, Goronzy JJ, Weyand CM: CD4+, CD28- T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems. Arthritis Rheum. 2001, 44: 13-20. 10.1002/1529-0131(200101)44:1<13::AID-ANR3>3.0.CO;2-6.CrossRefPubMed
55.
Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM, Goronzy JJ: Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med. 2001, 193: 1159-1168. 10.1084/jem.193.10.1159.PubMedCentralCrossRefPubMed
56.
Snyder MR, Lucas M, Vivier E, Weyand CM, Goronzy JJ: Selective activation of the c-Jun NH2-terminal protein kinase signaling pathway by stimulatory KIR in the absence of KARAP/ DAP12 in CD4+ T cells. J Exp Med. 2003, 197: 437-449. 10.1084/jem.20020383.PubMedCentralCrossRefPubMed
57.
Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T: Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA. 2003, 100: 9452-9457. 10.1073/pnas.1632807100.PubMedCentralCrossRefPubMed
58.
Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999, 285: 727-729. 10.1126/science.285.5428.727.CrossRefPubMed
59.
Tak PP, Kummer JA, Hack CE, Daha MR, Smeets TJ, Erkelens GW, Meinders AE, Kluin PM, Breedveld FC: Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum. 1994, 37: 1735-1743.CrossRefPubMed
60.
Dalbeth N, Callan MF: A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum. 2002, 46: 1763-1772. 10.1002/art.10410.CrossRefPubMed
61.
Pridgeon C, Lennon GP, Pazmany L, Thompson RN, Christmas SE, Moots RJ: Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright, CD94bright, CD158negative phenotype. Rheumatology (Oxford). 2003, 42: 870-878. 10.1093/rheumatology/keg240.CrossRef
62.
Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA: Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood. 2001, 97: 3146-3151. 10.1182/blood.V97.10.3146.CrossRefPubMed
63.
Farag SS, VanDeusen JB, Fehniger TA, Caligiuri MA: Biology and clinical impact of human natural killer cells. Int J Hematol. 2003, 78: 7-17.CrossRefPubMed
64.
Fujinami RS: Can virus infections trigger autoimmune disease?. J Autoimmun. 2001, 16: 229-234. 10.1006/jaut.2000.0484.CrossRefPubMed
65.
Paya CV, Patick AK, Leibson PJ, Rodriguez M: Role of natural killer cells as immune effectors in encephalitis and demyelination induced by Theiler's virus. J Immunol. 1989, 143: 95-102.PubMed
66.
Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR: From infection to autoimmunity. J Autoimmun. 2001, 16: 175-186. 10.1006/jaut.2000.0492.CrossRefPubMed
67.
Takeda K, Dennert G: The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med. 1993, 177: 155-164. 10.1084/jem.177.1.155.CrossRefPubMed
68.
Smeltz RB, Wolf NA, Swanborg RH: Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity. J Immunol. 1999, 163: 1390-1397.PubMed
69.
Fort MM, Leach MW, Rennick DM: A role for NK cells as regulators of CD4+ T cells in a transfer model of colitis. J Immunol. 1998, 161: 3256-3261.PubMed
70.
Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T: Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med. 1997, 186: 1677-1687. 10.1084/jem.186.10.1677.PubMedCentralCrossRefPubMed
71.
Matsumoto Y, Kohyama K, Aikawa Y, Shin T, Kawazoe Y, Suzuki Y, Tanuma N: Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis. Eur J Immunol. 1998, 28: 1681-1688. 10.1002/(SICI)1521-4141(199805)28:05<1681::AID-IMMU1681>3.0.CO;2-T.CrossRefPubMed
72.
Shi FD, Takeda K, Akira S, Sarvetnick N, Ljunggren HG: IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J Immunol. 2000, 165: 3099-3104.CrossRefPubMed
73.
Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, Bendelac A: Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol. 1999, 163: 4647-4650.PubMed
74.
Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G: Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 2002, 195: 327-333. 10.1084/jem.20010938.PubMedCentralCrossRefPubMed
75.
Piccioli D, Sbrana S, Melandri E, Valiante NM: Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med. 2002, 195: 335-341. 10.1084/jem.20010934.PubMedCentralCrossRefPubMed
76.
Moretta A: Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol. 2002, 2: 957-964. 10.1038/nri956.CrossRefPubMed
77.
Schott E, Bonasio R, Ploegh HL: Elimination in vivo of developing T cells by natural killer cells. J Exp Med. 2003, 198: 1213-1224. 10.1084/jem.20030918.PubMedCentralCrossRefPubMed
78.
Shi FD, Wang HB, Li H, Hong S, Taniguchi M, Link H, Van Kaer L, Ljunggren HG: Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol. 2000, 1: 245-251. 10.1038/79792.CrossRefPubMed
79.
Korsgren M, Persson CG, Sundler F, Bjerke T, Hansson T, Chambers BJ, Hong S, Van Kaer L, Ljunggren HG, Korsgren O: Natural killer cells determine the development of allergen-induced eosinophilic airway inflammation in mice. J Exp Med. 1999, 189: 553-562. 10.1084/jem.189.3.553.PubMedCentralCrossRefPubMed
80.
Backstrom E, Chambers BJ, Kristensson K, Ljunggren HG: Direct NK cell-mediated lysis of syngenic dorsal root ganglia neurons in vitro. J Immunol. 2000, 165: 4895-4900.CrossRefPubMed
81.
Morse RH, Seguin R, McCrea EL, Antel JP: NK cell-mediated lysis of autologous human oligodendrocytes. J Neuroimmunol. 2001, 116: 107-115. 10.1016/S0165-5728(01)00289-2.CrossRefPubMed
82.
Hickey WF, Ueno K, Hiserodt JC, Schmidt RE: Exogenously-induced, natural killer cell-mediated neuronal killing: a novel pathogenetic mechanism. J Exp Med. 1992, 176: 811-817. 10.1084/jem.176.3.811.CrossRefPubMed
83.
Backstrom E, Chambers BJ, Ho EL, Naidenko OV, Mariotti R, Fremont DH, Yokoyama WM, Kristensson K, Ljunggren HG: Natural killer cell-mediated lysis of dorsal root ganglia neurons via RAE1/NKG2D interactions. Eur J Immunol. 2003, 33: 92-100. 10.1002/immu.200390012.CrossRefPubMed
84.
Kitaichi N, Kotake S, Morohashi T, Onoe K, Ohno S, Taylor AW: Diminution of experimental autoimmune uveoretinitis (EAU) in mice depleted of NK cells. J Leukoc Biol. 2002, 72: 1117-1121.PubMed
85.
Flodstrom M, Maday A, Balakrishna D, Cleary MM, Yoshimura A, Sarvetnick N: Target cell defense prevents the development of diabetes after viral infection. Nat Immunol. 2002, 3: 373-382. 10.1038/ni771.CrossRefPubMed
Metadaten
Titel
Natural killer cells and autoimmunity
verfasst von
Anthony R French
Wayne M Yokoyama
Publikationsdatum
01.02.2003
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 1/2003
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1034

Weitere Artikel der Ausgabe 1/2003

Arthritis Research & Therapy 1/2003 Zur Ausgabe

Research article

Intramuscular electroporation with the pro-opiomelanocortin gene in rat adjuvant arthritis

Research article

Decreased response to IL-12 and IL-18 of peripheral blood cells in rheumatoid arthritis

Review

Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals

Article selection

Articles selected from Faculty of 1000 in January 2004

Research article

Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols

Research article

Does protein kinase R mediate TNF-α- and ceramide-induced increases in expression and activation of matrix metalloproteinases in articular cartilage by a novel mechanism?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise